Establishment of a Monoclonal Antibody PMab-231 for Tiger Podoplanin.

In this study, we immunized mice with tigPDPN-overexpressing Chinese hamster ovary (CHO)-K1 cells (CHO/tigPDPN) and screened hybridomas producing mAbs against tigPDPN using flow cytometry. One of the mAbs, PMab-231 (IgG2a, kappa), specifically detected CHO/tigPDPN cells using flow cytometry as well as recognized tigPDPN protein using western blotting. In addition, PMab-231 was found to cross-react with cat PDPN (cPDPN). The dissociation constants (KD) of PMab-231 for CHO/tigPDPN and CHO/cPDPN cells were determined to be 1.2 × 10-8 and 1.9 × 10-8, respectively, indicating moderate affinity for CHO/tigPDPN and CHO/cPDPN cells. PMab-231 stained type I alveolar cells of the feline lungs and podocytes of the feline kidneys using immunohistochemistry. Our findings suggest the potential usefulness of PMab-231 for the functional analyses of tigPDPN and cPDPN. PMID: 31009336 [PubMed - in process]
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research

Related Links:

Immunotherapy, Ahead of Print.
Source: Immunotherapy - Category: Allergy & Immunology Authors: Source Type: research
Patients with advanced melanoma treated with a combination of ipilimumab and nivolumab are more likely to be alive five years later than patients treated with ipilimumab alone or nivolumab alone.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
Authors: Afsharpooyan S, Mohammadian T Abstract Helicobacter pylori infection occurs throughout the world between countries and races. A seroprevalence study of H. pylori infection in the occurrence of atherosclerosis (ASc) has been considered to be the main cause of cardiovascular diseases (CVDs) in part of Iran. From 600 volunteers, 97 serum samples were selected and tested for the presence of H. pylori infection. Positive and negative H. pylori infection samples were then selected for Chlamydia pneumonia and cytomegalovirus infection. Their serum levels for high-sensitive C-reactive protein (hs-CRP) and IL-6 tit...
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research
In recognition of his groundbreaking work on the mechanisms underlying the cellular response to infection, Dr. Zhijian “James” Chen of the University of Texas Southwestern Medical Center in Dallas has received the 2019 Switzer Prize awarded by the David Geffen School of Medicine at UCLA.At the prize ceremony on the UCLA campus, during which Chen delivered a lecture about his research focused on the role of DNA in triggering immune defense and autoimmune diseases, the scientist said he was honored to receive the award and then joked that “to this day, I still don’t know who nominated me.”C...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
AbstractThe considerable variability of responses amongst subjects to disease triggers and immunotherapies is a major obstacle to designing better immune-based therapies. Therefore, development of patient-tailored precision medicine that improves the efficacy of immunomodulatory drugs is necessary. The individualized response to disease triggers and immunomodulatory therapies was studied using the concanavalin A (ConA) immune-mediated hepatitis model and the oral administration of anti CD3 or β-glucosylceramide (GC). Mice were treated with anti-CD3 antibodies or GC followed by an injection of ConA. The effects of thes...
Source: Immunologic Research - Category: Allergy & Immunology Source Type: research
ConclusionsInBRAF mutated patients with normal LDH, first-line immunotherapy seems a more effective approach. We have demonstrated that althoughBRAF mutation is a negative prognostic factor in stage IV melanoma, the use of two different systemic treatment modalities allows achievement of comparable survival inBRAF mutated andBRAF wild-type patients.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
AbstractProgrammed cell death protein 1 (PD-1) blockade is only effective in a minority of patients, prompting the search for combinatorial therapies that increase responses. Identifying effective combinations requires lengthy testing and so far has shown few successes. To accelerate progress Voorwerk and colleagues (Nat Med. 25(6):920-8, 2019) used an adaptive trial design to compare 4 short-course therapies (radiotherapy, cyclophosphamide, cisplatin and doxorubicin) for their ability to improve the tumor immune microenvironment and enhance responses to subsequent PD-1 blockade in women with metastatic triple negative bre...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
ConclusionThe confinement within the radiation field and the latency of appearance are suggestive of delayed radiation myelopathy. Nevertheless, the relatively low dose of radiation received and the full recovery after pembrolizumab discontinuation and steroid therapy plead for the contribution of both radiotherapy and immunotherapy in the causality of this complication, as an enhanced inflammatory reaction on a focal post-radiation chronic inflammatory state. In the three previously described cases of myelopathy occurring after radiotherapy and immunotherapy, a complete recovery had not been obtained and the immunotherapy...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
ConclusionsOur study provides the first report of the severe, early reactivation of an inactive HBsAg carrier after CAR T cell therapy in DLBCL.Trial registrationChiCTR-OPN-16008526.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
ConclusionsThis study is the first to achieve selective depletion of specific M2-like macrophage subsets, opening the possibility of eradicating cancer-supporting TAMs whilst sparing those with anti-tumour potential. Targeted TAM depletion with T cell engager-armed EnAd offers a powerful therapeutic approach combining direct cancer cell cytotoxicity with reversal of immune suppression.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: China Health | Immunotherapy | Microbiology | Ovaries | Study | Urology & Nephrology